Adenosine and SVT

Adenosine is a medication commonly used for the treatment of supraventricular tachycardia (SVT), which is a rapid heart rhythm originating from the upper chambers of the heart. Adenosine is classified as an antiarrhythmic agent, and it works by slowing down the electrical conduction in the heart, which helps to terminate the SVT.

The mechanism of action of adenosine is based on its ability to activate specific receptors called adenosine receptors, which are present in various tissues, including the heart. In the heart, adenosine activates adenosine receptors on the surface of cardiac cells, leading to an inhibition of the electrical conduction through the atrioventricular (AV) node, the structure responsible for regulating the communication between the atria and the ventricles.

The AHA (American Heart Association) guidelines recommend adenosine as the first-line treatment for the acute termination of regular narrow-complex SVT in both stable and unstable patients. The recommended dose of adenosine is 6 mg given rapidly by intravenous (IV) bolus, followed by a saline flush, and then increased to 12 mg if the first dose is ineffective. In cases of unstable patients, immediate cardioversion may be considered.

The effectiveness of adenosine in terminating SVT has been demonstrated in several studies. For example, a randomized controlled trial published in the New England Journal of Medicine showed that adenosine was effective in terminating 91% of SVT episodes, with a mean time to termination of 16 seconds.

In summary, adenosine is used in SVT due to its ability to inhibit the electrical conduction through the AV node, leading to the termination of the arrhythmia. Its effectiveness has been well established in numerous clinical studies, and it is recommended as the first-line treatment in the AHA guidelines for the acute termination of regular narrow-complex SVT.